Washington University University of Texas Southwestern VCID Consortium Site

项目摘要 血管对认知障碍和痴呆（VCID）的贡献是痴呆的第二大原因，并且是阿尔茨海默病（AD）的主要贡献者，阿尔茨海默病是痴呆的最常见原因。非侵入性生物标志物对于VCID预防和治疗策略的发展至关重要。MarkVCID联盟的第一个资助周期确定了11个候选成像和流体生物标志物。在第二个资助周期（RFA-NS-21-005）中，VCID联盟将“对这11种生物标志物中的6种进行全面的多中心临床验证。为了应对这一RFA，华盛顿大学医学院和德克萨斯大学西南医学中心（WU-UTSW）之间建立了强有力的合作伙伴关系，作为小血管VCID联盟的新基地。这两个机构都是高容量的三级保健转诊中心，为具有种族、民族、社会经济和城乡多样性的大都市地区提供服务。圣路易斯和达拉斯位于中风带之内或附近，有相当一部分人口处于中风、脑血管疾病和VCID的最高风险中。 由于VCID处于脑血管风险和年龄相关痴呆症之间的交界处，因此这种合作伙伴关系充分利用了WU和UTSW现有的脑血管和阿尔茨海默病（AD）研究基础设施的优势。这两个机构都有活跃的AD研究中心，WU是StrokeNet区域协调中心，展示了基于协作网络的临床研究的良好记录。此外，来自两个中心的研究者正在积极领导几项涉及VCID或ADRD受试者的独立纵向临床研究。我们召集了一组中风和AD临床医生、临床研究者和科学家，他们在VCID和AD病理生物学、临床试验实施和管理、液体生物标志物收集和测量、MR图像采集和处理、信息学和数据共享以及统计学方面具有不同的专业知识。WU-UTSW小组的集体专业知识不仅允许实施当前的VCID生物标志物研究，而且还将在完善当前和未来VCID生物标志物研究的设计方面提供独特的专业知识。我们将通过以下目标实现VCID联盟的目标：目标1：招募并纵向跟踪VCID风险的不同参与者队列。目的2：纵向采集并可重复测量该VCID队列的基于液体的生物标志物。目标3：纵向采集并可重复处理VCID队列的基于MRI的生物标志物。

PROJECT SUMMARY Vascular contributions to cognitive impairment and dementia (VCID) are the second leading cause of dementia, and a major contributor to Alzheimer’s disease (AD), the most common cause of dementia. Non- invasive biomarkers are critical for the development of prevention and treatment strategies for VCID. The first grant cycle of the MarkVCID consortium identified 11 candidate imaging and fluid biomarkers. In this second grant cycle (RFA-NS-21-005), the VCID consortium will “…carry out comprehensive multi-site clinical validation of up to six of these 11 biomarkers….” In response to this RFA, a strong partnership between Washington University School of Medicine and the University of Texas, Southwestern Medical Center (WU-UTSW) has been developed to serve as a new site for the Small Vessel VCID Consortium. Both institutions are high-volume tertiary care referral centers that serve large metropolitan areas with racial, ethnic, socioeconomic, and urban/rural diversity. St. Louis and Dallas are located within or adjacent to the stroke belt—with significant portions of the population at the highest risk of stroke, cerebrovascular disease, and VCID. Because VCID sits at the interface between cerebrovascular risk and age-related dementia, this partnership leverages strengths in both the cerebrovascular and Alzheimer’s disease (AD) research infrastructures that already exist at WU and UTSW. Both Institutions have active AD research centers, and WU is a StrokeNet regional coordinating center, demonstrating a strong track record of collaborative network-based clinical studies. In addition, investigators from both centers are actively leading several independent longitudinal clinical studies that involve participants with VCID or ADRD. We have assembled a group of stroke and AD clinicians, clinical investigators, and scientists who have diverse expertise in VCID and AD pathobiology, clinical trials implementation and management, fluid biomarker collection and measurement, MR image acquisition and processing, informatics and data sharing, and statistics. The collective expertise of the WU-UTSW group will not only permit the implementation of the current VCID biomarker study but will also provide unique proficiencies in refining the design of the current and future biomarker studies for VCID. We will achieve the goals of the VCID consortium through the following aims: Aim 1: Recruit and longitudinally follow a diverse cohort of participants at risk for VCID. Aim 2: Longitudinally acquire and reproducibly measure fluid-based biomarkers for this VCID cohort. Aim 3: Longitudinally acquire and reproducibly process MRI-based biomarkers for the VCID cohort.